Isomorphic Labs
Isomorphic Labs applies generative AI drug discovery to design novel molecules and predict how candidates will perform.
Iso sits in a tiny group of AI-native drug discovery partners that can point to AlphaFold lineage, named Lilly/Novartis/J&J deals and a fresh Series B behind them. But that list of credentials is also the gate: this is a multi-year research relationship, not a subscription. If you need software your own scientists can run on day one, look at Recursion or Schrödinger.
Verified 39m ago · liveness 71/100 · cite: rightaichoice.com/tools/isomorphic-labs
- Large pharma building AI-native drug discovery programs on a long-horizon partnership
- Late-stage pipeline teams wanting AI embedded from target ID through lead optimization
- Organizations whose molecular design bottleneck exceeds internal AI capability
- Public-health and preparedness bodies exploring bioresilience work with an AI partner
- Startups or academic labs without the budget for a multi-year research collaboration
- Teams that want a licensable platform they run and control themselves
- Short repurposing sprints or quick experimental workflows
We scan live Reddit threads, YouTube comments, X posts, G2 reviews and other communities — and hand you an honest verdict in under a minute.
- Honest verdict, not marketing
- Real pros & cons from real users
- Attributed quotes with receipts
3 free scans · no card needed
Skip Isomorphic Labs if you need a self-serve platform or published pricing — engagement runs through research collaborations with large pharma, so small teams and quick experiments are out of scope.
There is no published pricing, so budget is negotiated per partnership — plan for substantial committed spend rather than a listed subscription.
Isomorphic Labs publishes no pricing tiers — it is contact-sales and partnership-based, so cost scales with the size and length of the collaboration. That puts it out of range for small biotechs and academic labs, who should look at Schrödinger or Recursion for licensable, self-serve alternatives. Large pharma with multi-year R&D budgets are the realistic buyers here.
In short
Isomorphic Labs — Isomorphic Labs applies generative AI drug discovery to design novel molecules and predict how candidates will perform. Best for Large pharma building AI-native drug discovery programs on a long-horizon partnership, Late-stage pipeline teams wanting AI embedded from target ID through lead optimization, Organizations whose molecular design bottleneck exceeds internal AI capability. Contact Sales pricing.
What's new in Isomorphic Labs
Checked todayAcross the latest 3 updates: 3 news mentions.
Isomorphic Labs joins the Virtual Biology Initiative to build foundational data for AI models to predict and treat disease
Isomorphic Labs joins the Virtual Biology Initiative, contributing foundational data for AI models aimed at predicting and treating disease.
Building a new path to make medicines with AI
Isomorphic Labs publishes an announcement on its approach to AI-driven medicine development.
Our approach to bioresilience
Isomorphic Labs outlines its bioresilience approach, tied to its AI drug design work.
What people actually say about Isomorphic Labs — is it worth it?
We scanned public community sources for Isomorphic Labs on Oct 7, 2026 and could not establish that the discussion we found is about this tool rather than something else sharing its name. Only 1 of the posts we fetched could be positively tied to Isomorphic Labs. Rather than publish a sentiment score built on the wrong subject, we publish nothing here and re-run the scan.
Viability Score
How well maintained and how widely used is Isomorphic Labs? Built from what the vendor actually publishes (docs, changelog, tutorials, integrations, pricing), whether the site is live, and how much real users discuss it. How we calculate this
Last calculated: October 2026
How we score →Key Features
- Drug Design Engine spanning generative molecule design through lead optimization
- Predictive AI models that anticipate how candidate drugs will perform
- Generative models for designing novel molecules
- Builds on and beyond the Nobel-winning AlphaFold system
- End-to-end research collaborations from target identification to lead optimization
- Digital biology approach aimed at discovery at digital speed
- Named pharma partners include Johnson & Johnson, Novartis and Eli Lilly
- Joined the Virtual Biology Initiative to build foundational data for AI disease models
- Funder of Biohub's $1.8B initiative to train AI models that predict cell behavior
- Bioresilience framework for biological threats and health emergencies
- Series B investment round announced May 2026 to scale the Drug Design Engine
- Follows a $600M external raise in March 2025
- President Max Jaderberg appointed November 2025 to integrate AI and science
- Interdisciplinary team of drug discovery experts and ML specialists
- Founded by Demis Hassabis, who serves as CEO
About Isomorphic Labs
Isomorphic Labs is an AI-first drug discovery company built on predictive and generative models that design novel molecules and anticipate how candidate drugs behave. The company's own framing is "building on and beyond the Nobel-winning AlphaFold system" — its interdisciplinary team of drug discovery experts and machine learning specialists works at what it calls digital speed, under the banner of digital biology. The name comes from isomorphism: the belief that biology and information science share an underlying symmetry, so AI can model complex biological phenomena and turn them into molecules worth testing. That work runs through the Drug Design Engine, a generative platform spanning target identification through lead optimization, and through named pharma partnerships including Johnson & Johnson, Novartis and Eli Lilly. Demis Hassabis, who founded the company, serves as CEO, with Max Jaderberg appointed President in November 2025 to lead integration of AI and science. Recent activity has widened beyond in-house pipelines. Isomorphic Labs joined the Virtual Biology Initiative to build foundational data for AI models that predict and treat disease, and it appears among the funders of Biohub's $1.8B initiative to train AI models that predict cell behavior — alongside Meta, Google DeepMind and the US Department of Energy. A separate bioresilience framework covers biological threats and health emergencies. Funding has scaled toward the Drug Design Engine, from a $600M raise in March 2025 to a Series B announced May 2026. The practical read: Iso runs research collaborations, not licensable software. The counterparty is a large pharma or late-stage pipeline team that wants AI woven into R&D over years. Teams that need a platform they operate themselves are better served by Recursion or Schrödinger.
Behind the Verdict
The question worth answering first is not "how good are the models" — it is "what kind of relationship am I actually buying." Iso does not hand over a platform. It runs joint research, which means your scientists sit inside a shared program with Iso's team rather than logging into a dashboard. That shape fits some organizations and quietly frustrates others.Pick Iso when the bottleneck is genuinely molecular design at scale and your internal AI capability cannot close the gap in a reasonable timeframe. Large pharma with a long-horizon pipeline is the obvious fit — the named deals with Lilly, Novartis and J&J show the model works at that tier. Late-stage teams that want AI embedded from target ID through lead optimization, rather than bolted on at one step, are the second natural buyer.Pass when you need a tool you control. Short repurposing sprints are the wrong shape too — collaborations are built for depth, not for a six-week experiment.The closest alternatives frame the tradeoff cleanly. Recursion and Schrödinger sell software and platforms your team operates; Iso sells access to a research organization and its models. You are trading control and configurability for a partner with deeper model work and, on paper, a stronger scientific pedigree.Two caveats worth naming before you sign anything. First, biology is unforgiving — no amount of model quality guarantees a candidate survives the clinic, so judge proposals on experimental design and milestones, not on benchmark claims. Second, public signals about Iso arrive mostly as announcements:
Researching Isomorphic Labs? Get your full AI stack in 60 seconds.
Free, no signup — tell us your goal and get tools matched to your budget & existing stack.
Real-world workflow fit
Concrete scenarios for the personas Isomorphic Labs actually fits — and what changes day-one when you adopt it.
You engage Isomorphic Labs through a research collaboration (the same shape as the January 2026 Johnson & Johnson deal) covering multiple therapeutic targets from target identification onward.
Outcome: Your internal scientists co-develop candidates using the Drug Design Engine, compressing early discovery timelines and improving candidate quality before clinical work begins.
You apply the bioresilience framework Isomorphic Labs published to model biological threats and pre-position AI-driven drug design against future outbreaks.
Outcome: You get a structured approach to biological threat readiness rather than a scramble-response, with AI drug design embedded in the planning.
You approach Isomorphic Labs to apply generative molecule design and drug-behavior simulation to a stalled lead-optimization program.
Outcome: Simulations of anticipated drug performance let you triage candidates before synthesis, redirecting wet-lab budget toward the most promising leads.
Use Cases
- Design novel drug candidates using generative AI with a pharma partner.
- Predict protein structures for new therapeutic targets.
- Simulate drug behavior and anticipated performance before synthesis.
- Optimize lead compounds for binding affinity.
- Co-develop therapies across multiple targets in a J&J-style research collaboration.
- Develop pandemic preparedness frameworks through the bioresilience program.
Models Under the Hood
as of 2026-10-09
Limitations
- There is no public self-service tier, pricing, or product trial published on the site; engagement runs through partnerships and careers pages.
- The platform is presented as an enterprise pharma R&D endeavor rather than an individual-user tool accessible directly through the website.
- The site provides no public product documentation, integrations catalog, or technical specs, making it hard to assess fit against an existing stack from the website alone.
as of 2026-09-14
Verification history
We have re-verified Isomorphic Labs 98 times since . Each pass re-reads the vendor's own pages and re-checks every listed field against that evidence; passes where nothing had changed are marked as such.
- — re-verified summary, description, our verdict, our analysis, pricing model, pricing tiers, features, integrations, who it suits, who should skip it
- — re-verified summary, description, our verdict, our analysis, pricing model, pricing tiers, features, integrations, who it suits, who should skip it
- — re-checked, vendor evidence unchanged
- — re-checked, vendor evidence unchanged
- — re-checked, vendor evidence unchanged
- — re-checked, vendor evidence unchanged
Showing the 6 most recent of 98 verification passes.
Free to cite with attribution — this page re-verifies continuously.
Where the pricing makes sense
The company stage and team size where Isomorphic Labs's pricing actually pencils out — and where peers do it cheaper.
Isomorphic Labs publishes no pricing tiers — it is contact-sales and partnership-based, so cost scales with the size and length of the collaboration. That puts it out of range for small biotechs and academic labs, who should look at Schrödinger or Recursion for licensable, self-serve alternatives. Large pharma with multi-year R&D budgets are the realistic buyers here.
Setup time & first value
How long it actually takes to get something useful out of Isomorphic Labs — broken out by persona, not the marketing-page minute.
For large pharma: expect weeks of partnership scoping (contact partnering@isomorphiclabs.com) before any scientific work begins, since there is no self-serve onboarding. For smaller teams: there is no onboarding path at all — you would need a partnership relationship first. Anyone expecting an account signup and a first result the same week should look elsewhere.
Switching to or from Isomorphic Labs
How to bring data in from common predecessors and how to get it back out — written for the switcher, not the buyer.
- →From internal structure-prediction workflows: engage Isomorphic to extend from structure prediction into generative molecule design and lead optimization.
- →From a legacy computational chemistry suite: shift lead-optimization programs into the Drug Design Engine simulation workflow via a research collaboration.
- →From an academic or CRO-based discovery pipeline: move to an AI-native end-to-end collaboration that runs target identification through lead optimization.
- ↗To Schrödinger: if you need a licensable, self-serve computational platform with published pricing, move your modeling work to Schrödinger.
- ↗To Recursion: if you want an AI drug discovery partner accessible without large-pharma partnership scale, evaluate Recursion.
- ↗To an in-house model stack: if you want to run predictive models yourself, build or license an internal pipeline rather than a collaboration.
Resources & Guides
Tutorials & Learning
YouTube returned 6 videos for “Isomorphic Labs”, and we withheld 6: 6 could not be judged, because “Isomorphic Labs” is a single word that other videos use for other things. We are showing none, because we could not prove any of them are about Isomorphic Labs.
Official links
Tools that pair well with Isomorphic Labs
Common stack mates teams adopt alongside Isomorphic Labs, with the specific reason each pairing earns its keep.
Insilico Medicine
Generative AI drug discovery suite covering target ID, molecule design, biologics engineering and clinical trial prediction.
Nimbus Therapeutics
Clinical-stage biotech designing highly selective small-molecule drugs for oncology, immunology, and metabolic disease through partnership-led discovery.
Iktos
Iktos pairs generative AI with robotic lab automation to compress small-molecule drug discovery.
Featured Head-to-Head Comparisons
Ironclaw Ai Vision vs Isomorphic Labs
These tools are polar opposites in audience and purpose. Ironclaw AI Vision is a free, offline-first PWA for individual fitness tracking with AI coaching and meal planning – ideal for privacy-conscious health enthusiasts. Isomorphic Labs is a high-end AI drug discovery service for pharmaceutical partners, leveraging AlphaFold and costing millions. Choose Ironclaw for personal health; choose Isomorphic Labs if you're a pharma company aiming to accelerate drug development.
Angle vs Isomorphic Labs
Angle and Isomorphic Labs serve completely different domains—Angle is a free, niche pose-measurement tool for fitness professionals, while Isomorphic Labs is an enterprise AI drug discovery platform for pharma giants. The choice depends entirely on whether you need real-time exercise form analysis (Angle) or high-stakes drug development partnerships (Isomorphic Labs).
Calbye vs Isomorphic Labs
These tools serve completely different markets. CalBye is a consumer nutrition app for individuals wanting effortless calorie tracking via photos, while Isomorphic Labs is an enterprise drug discovery platform for pharma R&D partnerships. Choose CalBye for personal health tracking; choose Isomorphic Labs for large-scale AI-driven drug development.
Ray vs Isomorphic Labs
Choose Ray if you need an adaptive, low-barrier AI personal trainer for flexible, voice-guided workouts — it's ideal for busy individuals wanting consistency without gym intimidation. Choose Isomorphic Labs if you're a pharma company seeking cutting-edge AI drug discovery partnerships leveraging AlphaFold; it's not for individual use or small-scale projects.
Medisphere vs Isomorphic Labs
MediSphere and Isomorphic Labs serve completely different healthcare verticals. Choose MediSphere if you run a small clinic needing AI-powered administration, no-show prediction, and EHR. Choose Isomorphic Labs only if you are a large pharma company seeking deep AI collaboration for drug discovery—it is not a product you can buy.
Swimio vs Isomorphic Labs
Isomorphic Labs and Swimio serve completely different worlds: one is a high-stakes pharma AI platform for billion-dollar drug programs, the other a consumer fitness app for swimmers. Choose based on your domain: if you're a pharma company needing AI-driven lead optimization, Isomorphic Labs is your partner; if you're a swimmer or coach wanting adaptive workouts on Apple Watch, Swimio wins.
Cyberdesk vs Isomorphic Labs
If you need to automate legacy Windows desktop applications like EHRs, ERPs, or financial platforms without APIs, Cyberdesk is the right choice — it's a self-learning agent that runs on your Windows machine, supports natural language workflows, and now offers Claude Sonnet 5 and Gemini 3.5 Flash. If you're a pharma company seeking AI-driven drug discovery partnerships, Isomorphic Labs is the partner, leveraging AlphaFold and proprietary generative models with proven collaborations like Johnson & Johnson. These tools are not competitors; they serve entirely different domains.
Adaptyv vs Isomorphic Labs
If you need rapid experimental validation of protein designs for AI model training, Adaptyv's <3-week automated lab with transparent per-protein pricing ($149/protein) is ready now. If you are a large pharma company seeking an exclusive AI drug discovery partnership, Isomorphic Labs' AlphaFold-based engine (backed by $600M+ funding and J&J/Novartis collaborations) is the right fit. For individual researchers or startups, Adaptyv is accessible; Isomorphic Labs is not.
Confide vs Isomorphic Labs
Isomorphic Labs and Confide serve completely different needs: Isomorphic is an enterprise AI drug discovery partner for pharma giants, while Confide is a consumer mental wellness app. Your choice depends on whether you are a large drug developer or an individual journaler. There is no direct competition.
Curebench vs Isomorphic Labs
If you are an AI researcher or regulator needing a free, open-source benchmark to evaluate clinical reasoning models, CUREBench is the clear choice. If you are a large pharma company seeking a high-cost, high-impact AI drug discovery partner (with AlphaFold heritage and major collaborations), Isomorphic Labs is the only option. These tools are complementary rather than directly competing.
Symptom Checker Ai vs Isomorphic Labs
These tools operate in entirely different universes. Symptom Checker AI is a free, experimental student project for learning about AI limitations in healthcare — never for real diagnosis. Isomorphic Labs is a deep-tech drug discovery powerhouse backed by DeepMind, with $600M in funding and partnerships with Novartis and Johnson & Johnson. Choose Symptom Checker AI for casual exploration or education; choose Isomorphic Labs only if you're a pharma company seeking AI-driven molecule design at scale.
Crowdsynthetic vs Isomorphic Labs
If you are an event planner or researcher needing a free, open-source crowd simulation tool, CrowdSynthetic is a solid choice despite being a proof-of-concept. For pharma companies seeking cutting-edge AI drug discovery partnerships, Isomorphic Labs offers unparalleled predictive and generative capabilities built on AlphaFold, but only through high-stakes collaborations. These tools serve entirely different domains — pick based on your industry and budget.
Alternatives to Isomorphic Labs
View all
Insilico Medicine
Generative AI drug discovery suite covering target ID, molecule design, biologics engineering and clinical trial prediction.
Nimbus Therapeutics
Clinical-stage biotech designing highly selective small-molecule drugs for oncology, immunology, and metabolic disease through partnership-led discovery.
Frequently Asked Questions
Categories
Topics
Used Isomorphic Labs? Help shape our editorial sentiment research.